Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

6 Months Ended

Jun. 30, 2020

The following is a summary of stock option activity for the six months ended June 30, 2020 and 2019:


				Weighted-Average
	Number of	Weighted- Average		Contractual Life
	Options	Exercise Price		(In Years)
Outstanding at December 31, 2019	174,175	$	27.42	6.22
Granted	93,165		6.31
Expired	(17,114)		10.59
Forfeited	(3,333)		7.20
Outstanding at June 30, 2020	246,893	$	20.90	7.71
Exercisable at June 30, 2020	134,574	$	32.90	6.25
Vested at June 30, 2020	246,893	$	20.90	7.71

Outstanding at December 31, 2018	138,324	$	34.17	5.95
Granted	49,994		7.20
Expired	(3,237)		16.25
Outstanding at June 30, 2019	185,081	$	27.20	6.35
Exercisable at June 30, 2019	110,032	$	39.75	5.29
Vested at June 30, 2019	185,081	$	27.20	6.35

Schedule of weighted average assumptions

For the six months ended June 30, 2020 and 2019, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes Option Pricing Model with the following weighted-average assumptions:


	2020		2019
Risk-Free Interest Rate	1.82	%	1.82	%
Expected Life	5.00	years	5.00	years
Expected Volatility	153	%	152	%
Expected Dividend Yield	0	%	0	%

Schedule of restricted stock activity

The following is a summary of restricted stock activity for the six months ended June 30, 2020 and 2019:


				Weighted- Average
	Number of	Weighted- Average		Remaining
	Shares	Grant Date Fair Value		Recognition Period
Non-vested Outstanding at December 31, 2019	50,187	$	8.64	1.49
Awarded	49,000		6.55
Vested	(16,022)		8.82
Non-vested Outstanding at June 30, 2020	83,165	$	7.37	1.94
Non-vested Outstanding at December 31, 2018	121,478		8.84	2.25
Vested	(1,068)		22.81
Non-vested Outstanding at June 30, 2019	120,410	$	8.72	1.77

Schedule of stock-based compensation expense


	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Research and Development	$	53,669	$	58,611	$	99,322	$	123,150
General and Administrative		143,382		177,579		243,649		345,946
Total Stock-Based Compensation Expense	$	197,051	$	236,190	$	342,971	$	469,096